Treatment options for men with advanced prostate cancer have largely focused on the pillars of hormonal blockade, chemotherapies and bone-targeting agents. Attempts to develop novel combination strategies have been frustrated by the unique androgen-dominated biology of this common cancer. The recent discovery that a significant minority of men with advanced prostate cancer carry or develop alterations in deoxyribonucleic acid (DNA)-damage repair (DDR) proteins has uncovered a new potential therapeutic area. Moreover, polyadenosine-diphosphate-ribose polymerase (PARP) inhibitors are being explored in a number of combination treatments, aiming to harness the potential synergies seen in preclinical models.

中文翻译：

---

PARP 抑制剂联合治疗前列腺癌

晚期前列腺癌男性的治疗选择主要集中在激素阻断、化疗和骨靶向药物等支柱上。这种常见癌症独特的雄激素主导的生物学特性使开发新的组合策略的尝试受到挫败。最近发现，极少数患有晚期前列腺癌的男性携带或发生脱氧核糖核酸 (DNA) 损伤修复 (DDR) 蛋白的改变，这揭示了一个新的潜在治疗领域。此外，聚腺苷二磷酸核糖聚合酶（PARP）抑制剂正在多种联合治疗中进行探索，旨在利用临床前模型中发现的潜在协同作用。